TY - JOUR
T1 - Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain
T2 - A randomized, double-blind, parallel-group study
AU - Mucci-LoRusso, Patricia
AU - Berman, Barry S.
AU - Silberstein, Peter T.
AU - Citron, Marc L.
AU - Bressler, Linda
AU - Weinstein, Sharon M.
AU - Kaiko, Robert F.
AU - Buckley, Barbara J.
AU - Reder, Robert F.
N1 - Funding Information:
This study was sponsored by Purdue Pharma L.P., Norwalk, CT, USA.
PY - 1998
Y1 - 1998
N2 - Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled- release oxycodone (n = 48) or controlled-release morphine (n = 52) every 12 h for up to 12 days. Stable analgesia was achieved by 83% of controlled- release oxycodone and 81% of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3 =severe) decreased from baseline within each group (p ≤ 0.005), from 1.9 (0.1) to 1.3 (0.1), mean (SE), with controlled-release oxycodone, and from 1.6 (0.1) to 1.0 (0.1) with controlled-release morphine (no significant between-group differences). Typical opioid adverse experiences were reported in both groups. Hallucinations were reported only with controlled-release morphine (n=2). Visual analog scores (VAS) for 'itchy' and 'scratching' were lower with controlled-release oxycodone (p ≤ 0.044), as was peak-to-trough fluctuation in steady-state plasma concentration (p=0.004). The correlation between plasma concentration and dose was stronger (p=0.026) for oxycodone (0.7) than morphine (0.3). The relationship between pain intensity (VAS) and plasma concentration was more positive for oxycodone (p=0.046). There was a positive relationship between morphine-6-glucuronide concentrations and urea nitrogen and creatinine levels (p=0.0001). Controlled-release oxycodone was as effective as controlled-release morphine in relieving chronic cancer- related pain, and as easily titrated to the individual's need for pain control. While adverse experiences were similar, controlled-release oxycodone was associated with less itching and no hallucinations. Controlled-release oxycodone provides a rational alternative to controlled-release morphine for the management of moderate to severe cancer-related pain.
AB - Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled- release oxycodone (n = 48) or controlled-release morphine (n = 52) every 12 h for up to 12 days. Stable analgesia was achieved by 83% of controlled- release oxycodone and 81% of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3 =severe) decreased from baseline within each group (p ≤ 0.005), from 1.9 (0.1) to 1.3 (0.1), mean (SE), with controlled-release oxycodone, and from 1.6 (0.1) to 1.0 (0.1) with controlled-release morphine (no significant between-group differences). Typical opioid adverse experiences were reported in both groups. Hallucinations were reported only with controlled-release morphine (n=2). Visual analog scores (VAS) for 'itchy' and 'scratching' were lower with controlled-release oxycodone (p ≤ 0.044), as was peak-to-trough fluctuation in steady-state plasma concentration (p=0.004). The correlation between plasma concentration and dose was stronger (p=0.026) for oxycodone (0.7) than morphine (0.3). The relationship between pain intensity (VAS) and plasma concentration was more positive for oxycodone (p=0.046). There was a positive relationship between morphine-6-glucuronide concentrations and urea nitrogen and creatinine levels (p=0.0001). Controlled-release oxycodone was as effective as controlled-release morphine in relieving chronic cancer- related pain, and as easily titrated to the individual's need for pain control. While adverse experiences were similar, controlled-release oxycodone was associated with less itching and no hallucinations. Controlled-release oxycodone provides a rational alternative to controlled-release morphine for the management of moderate to severe cancer-related pain.
UR - http://www.scopus.com/inward/record.url?scp=0031718458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031718458&partnerID=8YFLogxK
U2 - 10.1016/S1090-3801(98)90020-9
DO - 10.1016/S1090-3801(98)90020-9
M3 - Article
C2 - 15102384
AN - SCOPUS:0031718458
VL - 2
SP - 239
EP - 249
JO - European Journal of Pain
JF - European Journal of Pain
SN - 1090-3801
IS - 3
ER -